CL2020000597A1 - Métodos y composiciones para tratar enfermedades pulmonares crónicas. - Google Patents

Métodos y composiciones para tratar enfermedades pulmonares crónicas.

Info

Publication number
CL2020000597A1
CL2020000597A1 CL2020000597A CL2020000597A CL2020000597A1 CL 2020000597 A1 CL2020000597 A1 CL 2020000597A1 CL 2020000597 A CL2020000597 A CL 2020000597A CL 2020000597 A CL2020000597 A CL 2020000597A CL 2020000597 A1 CL2020000597 A1 CL 2020000597A1
Authority
CL
Chile
Prior art keywords
compositions
treating chronic
methods
lung diseases
chronic lung
Prior art date
Application number
CL2020000597A
Other languages
English (en)
Inventor
Norman Barton
Alexandra Mangili
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CL2020000597A1 publication Critical patent/CL2020000597A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos y composiciones para tratar la Enfermedad Pulmonar Crónica (CLD), que comprende administrar a un sujeto que necesita el tratamiento una composición que comprende el factor de crecimiento similar a la insulina tipo 1 (IGF-1).
CL2020000597A 2017-09-11 2020-03-09 Métodos y composiciones para tratar enfermedades pulmonares crónicas. CL2020000597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11

Publications (1)

Publication Number Publication Date
CL2020000597A1 true CL2020000597A1 (es) 2020-12-04

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000597A CL2020000597A1 (es) 2017-09-11 2020-03-09 Métodos y composiciones para tratar enfermedades pulmonares crónicas.

Country Status (20)

Country Link
US (2) US20190151411A1 (es)
EP (1) EP3681602A1 (es)
JP (2) JP2020533344A (es)
KR (1) KR20200097679A (es)
CN (1) CN111432881A (es)
AU (1) AU2018328827B2 (es)
BR (1) BR112020004760A2 (es)
CA (1) CA3075482A1 (es)
CL (1) CL2020000597A1 (es)
CO (1) CO2020004244A2 (es)
EA (1) EA202090705A1 (es)
EC (1) ECSP20055797A (es)
IL (1) IL273174B1 (es)
MX (1) MX2020002744A (es)
PE (1) PE20201166A1 (es)
PH (1) PH12020500489A1 (es)
SG (1) SG11202002088TA (es)
UA (1) UA128690C2 (es)
WO (1) WO2019051474A1 (es)
ZA (1) ZA202001568B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233228A (zh) * 2020-10-19 2022-09-01 美商舒爾人類基因療法公司 適用於新生兒的組成物
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2135306A1 (en) 1992-05-08 1993-11-25 Bradford A. Jameson Igf-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2429615C (en) * 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
CN101969983B (zh) * 2007-04-18 2014-11-05 普利玛库尔公司 治疗和/或预防早产并发症的方法和产品

Also Published As

Publication number Publication date
CN111432881A (zh) 2020-07-17
BR112020004760A2 (pt) 2020-09-15
IL273174A (en) 2020-04-30
JP2020533344A (ja) 2020-11-19
AU2018328827B2 (en) 2024-07-25
ZA202001568B (en) 2023-09-27
IL273174B1 (en) 2024-08-01
US20220088132A1 (en) 2022-03-24
JP2023145646A (ja) 2023-10-11
PE20201166A1 (es) 2020-10-28
EA202090705A1 (ru) 2020-06-11
CA3075482A1 (en) 2019-03-14
WO2019051474A1 (en) 2019-03-14
SG11202002088TA (en) 2020-04-29
EP3681602A1 (en) 2020-07-22
CO2020004244A2 (es) 2020-05-29
UA128690C2 (uk) 2024-10-02
AU2018328827A1 (en) 2020-04-02
ECSP20055797A (es) 2020-10-30
PH12020500489A1 (en) 2021-02-22
KR20200097679A (ko) 2020-08-19
MX2020002744A (es) 2020-10-01
US20190151411A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CY1118676T1 (el) Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112015019064A2 (pt) métodos de tratamento de melanoma
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
CO2020016582A2 (es) Sales de sepiapterina farmacéuticamente aceptables
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
AR101740A1 (es) Terapia de combinación y composiciones
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
BR112017006842A2 (pt) formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
JP2017527618A5 (es)
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
BR112016016098A2 (pt) Compostos orgânicos
AR103555A1 (es) Composiciones y métodos para el uso crónico de un compuesto para aumentar el peso
PE20181329A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol